Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002

NCT00635089 is registered in ClinicalTrials.gov with Ception Therapeutics as lead sponsor.

NCT NCT00635089
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00635089 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Safety and Efficacy Study of Reslizumab (CTx55700) for the Treatment of Pediatric Subjects With Eosinophilic Esophagitis Who Completed Study Res-5-0002
Lead sponsor
Ception Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2008
Completion date
January 31, 2012
Enrollment
190 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic esophagitis